A clinical study evaluating genetic testing strategies in patients suspected of having monogenic diabetes found that conducting research analysis on existing exome sequencing datasets yielded a diagnostic rate comparable to clinical exome-based gene panels, without identifying additional confirmed diagnostic variants. Monogenic diabetes represents an estimated 1 to 4 percent of all diabetes cases diagnosed in children and adolescents, yet the diagnostic rate among affected individuals remains notably low. Identifying specific underlying molecular causes is critical to establishing appropriate patient treatment regimens and delivering accurate genetic counseling.
To investigate diagnostic performance, researchers examined the yield of five multigene panels among 83 endocrine patients who had previously undergone clinical exome-based gene panel testing. The study cohort comprised suspected monogenic diabetes cases, of which 81 percent were pediatric patients and 55 percent were female. Alongside the evaluation of ordered clinical gene panels, investigators conducted secondary research analysis on the previously generated exome sequencing data to assess whether broader reanalysis could increase overall diagnostic yield or reveal biologically suspicious variants in genes not yet formally associated with monogenic diabetes.
During the research exome reanalysis, identified variants of interest were systematically categorized into three defined groups based on clinical and biological relevance. The first category comprised candidate diagnostic findings, defined as variants associated with the clinical indication for testing but located in genes omitted from the ordered clinical panel. The second group encompassed variants situated in candidate diabetes disease genes. The third category included incidental findings considered clinically actionable for the patient, with all relevant clinical background collected directly from electronic health records.
The initial clinical exome-based gene panel testing yielded definitive diagnostic results in a small subset of the cohort. Seven of the 83 patients, representing 8 percent of the group, received positive test results confirming a molecular diagnosis. Inconclusive findings attributable to variants of uncertain significance were documented in 37 patients, accounting for 45 percent of the cohort, while 39 patients, or 47 percent, received negative test results across the ordered multigene panels.
Among the seven individuals with positive initial panel results, pathogenic variants in the WFS1 and GCK genes represented the most frequently observed diagnostic findings, with each gene accounting for pathogenic variants in two of the seven diagnosed patients.
Subsequent research-level analysis across the previously generated exome sequencing data identified a total of 12 variants of interest distributed across 10 patients. Within this subset, researchers detected a pathogenic variant in the IGF1R gene in one patient. Because IGF1R was not included on the clinically ordered panel, the alteration was classified as a candidate diagnostic finding in light of the patient’s documented short stature.
A separate patient in the cohort harbored compound heterozygous pathogenic variants in the ARSA gene, which the investigators designated as a clinically actionable incidental finding at the time of detection. In addition, the research reanalysis uncovered nine distinct variants situated in genes that are not currently associated with diabetes diagnoses, including CAPN10 and SLC2A4, providing non-diagnostic candidate targets for subsequent investigation.
The evidence supporting the involvement of these candidate genes in diabetes-related biological pathways derived from animal models, computational predictions, pathway enrichment analyses, gene network modeling, and functional annotation predictions. Investigators concluded that while research reanalysis of existing exome sequencing data did not increase diagnostic yield beyond standard exome-based panel testing in this cohort, it offered the distinct advantage of highlighting candidate disease genes that may inform future gene discovery.
Subject of Research: Exome-based gene panel testing and secondary research exome reanalysis in suspected monogenic diabetes
Article Title: Utility of exome-based gene panel testing and research analysis of existing exome sequencing data in suspected monogenic diabetes
Article References: Vernet Machado Bressan Wilke, M., Thompson, M. L., Jho, S., Polonis, K., Rahi, H., Dickson, A., Corliss, M. M., Cao, Y., Walker, J., Sprenger, G. A., Krysiak, K., Schroeder, M. C., Stone, S., Urano, F., Neidich, J. A., & Bowling, K. M. (2026). Utility of exome-based gene panel testing and research analysis of existing exome sequencing data in suspected monogenic diabetes. Orphanet Journal of Rare Diseases. https://doi.org/10.1186/s13023-026-04675-x
Image Credits: AI Generated
DOI: 10.1186/s13023-026-04675-x
Keywords: monogenic diabetes, exome sequencing, gene panel testing, diagnostic yield, pediatric endocrinology, GCK, WFS1, IGF1R, ARSA, CAPN10, SLC2A4, variants of uncertain significance, incidental findings, candidate disease genes, clinical genetics
News Source: Juliet Wilcox. (November 20, 2026). Existing Exome Data Yields No Extra Diagnoses in Suspected Monogenic Diabetes. Scienmag.



